Teva Launches Teva Rise Teva Launches Rise - Global Open Innovation Platform First cohort features 7 real-world challenges across R&D,...
Financial agenda for 2026 Villepinte, November 19, 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for...
Curium has entered a partnership with the Czech company ÚJV Řež, a leading expert in the development and production of...
FORT WORTH, TX, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI),...
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
PwdRx novel drug delivery platform demonstrated superior bioavailability and accelerated absorption of cannabinoids in preclinical studies Provisional patent application on...
RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a...
ROCKLEDGE, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- LUKE Holdings, Inc. (“LUKE”), a trusted leader in healthcare staffing for the...
National B2B cannabis conference develops high-impact programming to support industry-wide growth and innovation Grow Up Conference & Expo Heads to...
GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million...
– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show...
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged...
Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect...
Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free...
SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical...
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leading neurotechnology company powering AI-driven neurodiagnostics and precision medicines for...
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology...
LEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the...
Tokyo, Japan and Cambridge, UK, 19 November 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) announces...
November 19, 2025 Announcement no. 26 BioPorto Interim Result for the Third Quarter of 2025 – Continued progress and continued...